Aethlon Medical (OTC:AEMD) said today that data from in vitro Zika virus studies of its Hemopurifier blood filter indicated a 50% clearance of the virus from human blood serum in 5 hours. The San Diego, Calif.-based company said the Zika studies, which were conducted with small-scale versions of the Hemopurifier, also reported a 95% clearance rate of […]
Aethlon Medical Inc.
Aethlon Medical (OTC:AEMD) said today it extended its contract with DARPA to develop a device to reduce the incidence of sepsis, a commonly fatal infection encountered by combat-injured soldiers. The contract with DARPA was originally inked in September 2011 and has been extended to its 5th year with Aethlon, the company said. The reward is a […]
Aethlon Medical (OTC:AEMD) yesterday said it plans to file for Investigative Device Exemption status for its HemoPurifier after the company’s contract with DARPA expires, and reports slimmed losses for the company and investors. In a quarterly earnings call, CEO Jim Joyce said this would be the company’s last year on contract with DARPA, with a caveat of a […]
Aethlon Medical (OTC:AEMD) said yesterday that the NASDAQ Stock Market has approved its application to begin trading on the Nasdaq Capital Market, beginning July 13. The company’s shares will be traded on the Nasdaq Capital Market under its existing trading symbol AEMD, the San Diego, Calif.-based company said. “Trading on Nasdaq is a pivotal corporate […]
Aethlon Medical (OTC:AEMD) said today that it looks to raise $6m with a stock offering at $6.30 per share, including a 5-year warrant allowing the purchase of up to 3 shares per 4 shares purchased in this offering. Aethlon is authorized to issue up to 10 million shares, with funds slated for the clinical advancement of the […]